In this first clinical, phase I, dose-escalation and -expansion study, scientists evaluated CC-90002 in patients with relapsed/refractory acute myeloid leukemia or high-risk myelodysplastic syndromes.
[Annals of Hematology]
Sorry, but the selected Zotpress account can't be found.
